DGAP-News: Jeffrey Gold Joins myoscience as President and

DGAP-News: myoscience /
Jeffrey Gold Joins myoscience as President and Chief Operating Officer

23.04.2014 / 14:00

---------------------------------------------------------------------

REDWOOD CITY, Calif., 2014-04-23 14:00 CEST (GLOBE NEWSWIRE) --
myoscience, inc. is pleased to announce the addition of Jeffrey Gold to the
team as President and Chief Operating Officer (COO). Mr. Gold is an
accomplished executive, having held posts as Chief Executive for Velomedix and
CryoVascular Systems as well as Chief Operating Officer for CardioThoracic
Systems. 

'Jeff's leadership and extensive experience driving operational excellence
makes him an exceptional addition to myoscience as we expand our global
commercial presence in both aesthetic and therapeutic channels,' said Clint
Carnell, CEO of myoscience. 

Mr. Gold was most recently the President & CEO of Velomedix Inc, a venture
backed company that developed a unique technology for rapidly inducing
therapeutic hypothermia in patients undergoing severe acute cardiovascular
events, such as heart attack and cardiac arrest. Prior to Velomedix, Mr. Gold
was a Venture Partner for Longitude Capital where he focused on investments in
medical devices. 

'I am thrilled to be joining myoscience at such an exciting point in their
growth,' said Gold. 'My previous experience and the current needs of the
company align perfectly and I look forward to guiding the business towards
further success.' 

ABOUT MYOSCIENCE

Silicon Valley, California-based myoscience is a privately-held medical device
company committed to making its platform technology, Focused Cold Therapy(TM),
the standard of care for the treatment of peripheral nerve conditions. Focused
Cold Therapy is the patented technology delivered by the iovera:o system. The
iovera:o system is currently approved in Europe and Canada for temporary wrinkle
reduction, temporary pain reduction and treatment of dermatologic conditions,
and is indicated in the United States for use in pain management and general
surgical use. For more information, please visit www.myoscience.com. 

The myoscience logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13581 

(c) 2014 myoscience. All rights reserved. iovera* and Focused Cold Therapy are
trademarks of myoscience. 


         CONTACT: 1600 Seaport Blvd., Ste. 450  /  Redwood City, CA
         Tel: 650.474.2600 /  iovera.com
         MEDIA RELATIONS
         Peter Osborne / posborne@myoscience.com
News Source: NASDAQ OMX


End of Corporate News

---------------------------------------------------------------------

23.04.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English        
Company:     myoscience     
 
 
             United States  
ISIN:        US9902131674   
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
264244 23.04.2014
DGAP-News: Jeffrey Gold Joins myoscience as President and Chief Operating Officer
